English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Upper gastrointestinal endoscopy during the COVID-19 pandemic carries a risk of disease transmission [1, 2]. The HemoPill (Ovesco Endoscopy, Tübingen, Germany) is composed of an orally administered telemetric sensor capsule that is capable of detecting blood and hematin, and a wireless receiver for data display [3–5]. Results are expressed as the HemoPill indicator (HI). A HI value ≥0.8 during the first 10 minutes of the examination or ≥1.0 thereafter denotes a positive test result. We evaluated this sensor capsule in patients with confirmed or suspected COVID-19. Case #1 was a patient with COVID-19, congestive heart failure, and severe obesity who reported melena and had a drop of hemoglobin from 14.6g/dL to 11.3g/ dL. She required low-flow oxygen but was otherwise clinically stable. The maximum HI value was 1.0 after 89 minutes (▶Fig. 1a). Endoscopy subsequently showed a gastric ulcer with a non-bleeding visible vessel (▶Fig. 1b). Patient #2 suffered from dyspnea and anemia (hemoglobin 4.3g/dL) with possible gastrointestinal bleeding. She was routinely tested for SARS-CoV-2 and isolated until receipt of her result. The COVID-19 communication

Potential use of a novel telemetric sensor capsule in patients with suspected gastrointestinal bleeding during the COVID-19 pandemic